{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:23:31Z","timestamp":1793190211668,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ygyno.2024.09.011","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T01:39:17Z","timestamp":1726796357000},"page":"10-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC) endometrial cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"191","author":[{"given":"Mary Katherine","family":"Anastasio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine N.","family":"Penvose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Ledbetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany A.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin B.","family":"Albright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.09.011_bb0005","author":"American Cancer Society"},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.011_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.011_bb0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3802\/jgo.2015.26.1.25","article-title":"An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers","volume":"26","author":"Vogel","year":"2015","journal-title":"J. Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.011_bb0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijgo.2009.02.010","article-title":"Revised FIGO staging for carcinoma of the endometrium","volume":"105","author":"Creasman","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.011_bb0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"10","key":"10.1016\/j.ygyno.2024.09.011_bb0030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/ijgc-2021-002771","article-title":"High-grade endometrial carcinoma limited to the endometrium or a polyp: is adjuvant treatment necessary?","volume":"31","author":"Dallaire Nantel","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/IGC.0000000000000635","article-title":"An assessment of prognostic factors, adjuvant treatment, and outcomes of stage IA polyp-limited versus endometrium-limited type II endometrial carcinoma","volume":"26","author":"Liang","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0040","first-page":"284","article-title":"A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy","volume":"31","author":"Rauh-Hain","year":"2010","journal-title":"Eur. J. Gynaecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.011_bb0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ygyno.2024.09.011_bb0050","author":"Higgins"},{"key":"10.1016\/j.ygyno.2024.09.011_bb0055","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2024.09.011_bb0060","author":"Wells"},{"issue":"10","key":"10.1016\/j.ygyno.2024.09.011_bb0065","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.24247","article-title":"Platinum\/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma","volume":"115","author":"Fader","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0070","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2007.01.041","article-title":"Outcomes in surgical stage I uterine papillary serous carcinoma","volume":"105","author":"Havrilesky","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.011_bb0075","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2009.07.004","article-title":"Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006","volume":"115","author":"Tchabo","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.011_bb0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2007.05.044","article-title":"Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma","volume":"107","author":"Thomas","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.011_bb0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/IGC.0000000000000838","article-title":"Extrauterine spread, adjuvant treatment, and prognosis in noninvasive uterine papillary serous carcinoma of the endometrium: a retrospective multicenter study","volume":"27","author":"Boyraz","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2024.09.011_bb0090","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/00000478-199712000-00015","article-title":"Stage IA uterine serous carcinoma: a study of 13 cases","volume":"21","author":"Carcangiu","year":"1997","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0095","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ygyno.2013.10.010","article-title":"Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy","volume":"131","author":"Chang-Halpenny","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.011_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2004.05.009","article-title":"High-dose rate brachytherapy for stage I\/II papillary serous or clear cell endometrial cancer","volume":"94","author":"DuBeshter","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.011_bb0105","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygyno.2003.09.025","article-title":"Optimal management for surgically stage 1 serous cancer of the uterus","volume":"92","author":"Elit","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.011_bb0110","first-page":"153","article-title":"Noninvasive papillary serous carcinoma of the endometrium","volume":"97","author":"Gehrig","year":"2001","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0115","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ijrobp.2005.03.028","article-title":"Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma","volume":"63","author":"Hamilton","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0120","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/PGP.0000000000000235","article-title":"Clinical significance of positive pelvic washings in uterine papillary serous carcinoma confined to an endometrial polyp","volume":"35","author":"Hanley","year":"2016","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0125","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ygyno.2003.08.027","article-title":"Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy","volume":"91","author":"Huh","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.09.011_bb0130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/ijgc-2023-005149","article-title":"Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion","volume":"34","author":"Jamieson","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0135","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2005.06.012","article-title":"Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy","volume":"98","author":"Kelly","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0140","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2022.09.025","article-title":"Adjuvant therapy in women with early stage uterine serous carcinoma: a multi-institutional study","volume":"167","author":"Kurnit","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2024.09.011_bb0145","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/IGC.0b013e31822e7588","article-title":"Role of adjuvant chemotherapy in patients with early stage uterine papillary serous cancer","volume":"21","author":"Mahdavi","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ygyno.2014.12.034","article-title":"Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study","volume":"136","author":"Mahdi","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.09.011_bb0155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gore.2019.05.007","article-title":"Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: what should we do next?","volume":"29","author":"Mills","year":"2019","journal-title":"Gynecol. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.011_bb0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","article-title":"Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study","volume":"40","author":"Morrow","year":"1991","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2024.09.011_bb0165","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/ijgc-2020-001379","article-title":"Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium","volume":"30","author":"Nasioudis","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2024.09.011_bb0170","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e49","article-title":"Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish gynecologic oncology group study","volume":"28","author":"Sari","year":"2017","journal-title":"J. Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0175","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ygyno.2003.08.018","article-title":"Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases","volume":"91","author":"Slomovitz","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.011_bb0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2013.11.002","article-title":"Population-based treatment and outcomes of stage I uterine serous carcinoma","volume":"132","author":"van der Putten","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0185","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/IGC.0000000000000643","article-title":"Role of adjuvant therapy for stage IA serous and clear cell uterine Cancer: is observation a valid strategy?","volume":"26","author":"Velker","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2024.09.011_bb0190","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00000478-200006000-00004","article-title":"Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation","volume":"24","author":"Wheeler","year":"2000","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0195","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2024.09.011_bb0200","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial Cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"9213","key":"10.1016\/j.ygyno.2024.09.011_bb0205","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.011_bb0210","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"7447","key":"10.1016\/j.ygyno.2024.09.011_bb0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.011_bb0220","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.011_bb0225","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13023-020-01493-7","article-title":"A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome","volume":"15","author":"Atalaia","year":"2020","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:45:00Z","timestamp":1733881500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824011351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":45,"alternative-id":["S0090825824011351"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.09.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC) endometrial cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}